Journal Information
Vol. 41. Issue 2.
Pages 63-70 (February 2005)
Share
Share
Download PDF
More article options
Vol. 41. Issue 2.
Pages 63-70 (February 2005)
Original Articles
Full text access
Factors Affecting Drug Prescription in Patients With Stable COPD: Results From a Multicenter Spanish Study
Visits
4133
J. de Miguel Díeza, J.L. Izquierdo Alonsob,
Corresponding author
jlizquierdo@sescam.org

Correspondence: Dr. J.L. Izquierdo Alonso. Sección de Neumología. Hospital General Universitario de Guadalajara. Donantes de Sangre, s/n. 19002 Guadalajara. España
, J. Molina Parísc, J.M. Bellón Canod, J.M. Rodríguez González-Moroa, P. de Lucas Ramosa
a Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Servicio de Neumología, Hospital General Universitario de Guadalajara, Guadalajara, Spain
c Centro de Salud Francia, Fuenlabrada, Madrid, Spain
d Unidad de Investigación, Hospital General Universitario Gregorio Marañón, Madrid, Spain
This item has received
Article information
Objective

TO determine what factors are associated with prescription of drugs to patients with stable chronic obstructive pulmonary disease (COPD).

Material and Methods

We studied 568 patients with stable COPD. Assessments included determination of the severity of dyspnea, body mass index, health-related quality of life, and spirometry testing.

Results

The forced expiratory volume in 1 second was significantly associated with prescription of long-acting β2-adrenergic agonists (odds ratio [OR]=0.98; 95% confidence interval [CI], 0.96-1) and inhaled corticosteroids (OR=0.98; 95% CI, 0.96-1). Quality of life was related to administration of short-acting β2-adrenergic agonists (OR=1.02; 95% CI, 1-1.03), long-acting β2-adrenergic agonists (OR=1.02; 95% CI, 1-1.03), ipratropium bromide (OR=1.03; 95% CI, 1-1.04), theophylline drugs (OR=1.02; 95% CI, 1-1.03), and inhaled corticosteroids (OR=1.02; 95% CI, 1-1.03). The severity of dyspnea was significantly associated with prescription of oral corticosteroids (for grade IV dyspnea, OR=15.25; 95% CI, 2.40-97.02). Body mass index was not related to drug administration.

Conclusions

Drug prescription in patients with stable COPD correlates not only with forced expiratory volume in 1 second but also with other parameters such as health-related quality of life and dyspnea.

Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable. Resultados de un estudio multicéntrico español (IDENTEPOC)

Key Words:
COPD
FEV1
Health-related quality of life
Dyspnea
Treatment
Objetivo

Determinar qué factores se relacionan con la prescripción de fármacos en los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) estable.

Material Y Métodos

Se estudió a 568 pacientes con EPOC estable. La evaluación realizada incluyó la medición del grado de disnea, la determinación del índice de masa corporal, el estudio de la calidad de vida relacionada con la salud y la realización de una espirometría.

Resultados

El volumen espiratorio forzado en el primer segundo se asoció significativamente con la prescripción de β2-adrenérgicos de acción larga (odds ratio [OR] = 0,98; in-tervalo de confianza [IC] del 95%, 0,96-1) y corticoides in-halados (OR = 0,98; IC del 95%, 0,96-1). La calidad de vida se relacionó con la administración de β2-adrenérgicos de acción corta (OR = 1,02; IC del 95%, 1-1,03), β2-adrenérgicos de acción larga (OR = 1,02; IC del 95%, 1-1,03), bromuro de ipratropio (OR = 1,03; IC del 95%, 1-1,04), teofilinas (OR = 1,02; IC del 95%, 1-1,03) y corticoides inhalados (OR = 1,02; IC del 95%, 1-1,03). El grado de disnea mostró una asociación significativa con la prescripción de corticoides orales (para disnea grado IV, OR = 15,25; IC del 95%, 2,40-97,02). No se encontró ninguna relación entre la administración de fármacos y el índice de masa corporal.

Conclusiones

La prescripción farmacológica de los pacientes con EPOC estable viene determinada no sólo por el volumen espiratorio forzado en el primer segundo, sino tam-bién por otros parámetros, entre los que se incluyen la calidad de vida relacionada con la salud y la disnea.

Palabras clave:
EPOC
FEV1
Calidad de vida relacionada con la salud
Disnea
Tratamiento
Full text is only aviable in PDF
REFERENCES
[1]
JA Barberà, G Peces-Barba, AGN Agustí, JL Izquierdo, E Monsó, T Montemayor, et al.
Guía clínica para el diagnóstico y el tratamiento de la enfermedad pulmonar obstructiva crónica.
Arch Bronconeumol., 37 (2001), pp. 297-316
[2]
The COPD guidelines group of the standards of care committee of the BTS.
BTS guidelines for the management of chronic obstructive pulmonary disease.
Thorax, 52 (1997), pp. 1-28
[3]
NM Siafakas, P Vermeire, NB Pride, P Paoletti, J Gibson, P Howard, et al.
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). A consensus statement of the European Respiratory Society.
Eur Respir J., 8 (1995), pp. 1398-1420
[4]
American Thoracic Society.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 152 (1995), pp. S77-S120
[5]
RA Pauwels, AS Buist, PMA Calverley, CR Jenkins, SS Hurd.
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary.
Am J Respir Crit Care Med., 163 (2001), pp. 1256-1276
[6]
BR Celli.
The importance of spirometry in COPD and asthma: effect on approach to management.
Chest, 117 (2000), pp. S15-SS9
[7]
CP van Schayck.
Is lung function really a good parameter in evaluating the long-term effects of inhaled corticosteroids in COPD?.
Eur Respir J., 15 (2000), pp. 238-239
[8]
B Celli.
EPOC: desde el nihilismo no justificado a un optimismo razonable.
Arch Bronconeumol., 38 (2002), pp. 585-588
[9]
T Hajiro, K Nishimura, M Tsukino, A Ikeda, T Oga, T Izumi.
A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD.
Chest, 116 (1999), pp. 1632-1637
[10]
AM Schols, J Slangen, L Volovics, EF Wouters.
Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 157 (1998), pp. 1791-1797
[11]
DA Gerardi, L Lovett, ML Benoit-Connors, JC Reardon, RL ZuWallack.
Variables related to increased mortality following outpatient pulmonary rehabilitation.
Eur Respir J., 9 (1996), pp. 431-435
[12]
J de Miguel Díez, JL Izquierdo Alonso, J Molina París, JM Rodríguez González-Moro, P de Lucas Ramos, G Gaspar Alonso-Vega.
Fiabilidad del diagnóstico de la EPOC en atención primaria y neumología en España. Factores predictivos.
Arch Bronconeumol., 39 (2003), pp. 203-208
[13]
Díez de Miguel, JL Izquierdo Alonso, JM Rodríguez González-Moro, P de Lucas Ramos, J Molina París.
Tratamiento farmacológico de la EPOC en dos niveles asistenciales. Grado de adecuación a las normativas recomendadas.
Arch Bronconeumol., 39 (2003), pp. 195-202
[14]
JC Bestall, EA Paul, R Garrod, R Garnham, PW Jones, JA Wedzicha.
Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.
Thorax, 54 (1999), pp. 581-586
[15]
PW Jones, FH Quirk, CM Baveystock, P Littlejohns.
A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire.
Am Rev Respir Dis., 145 (1992), pp. 1321-1327
[16]
M Ferrer, J Alonso, L Prieto, V Plaza, E Monsó, R Marrades, et al.
Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example.
Eur Respir J., 9 (1996), pp. 1160-1166
[17]
American Thoracic Society.
Standardization of spirometry and PEF: 1994 update.
Am J Respir Crit Care Med., 152 (1995), pp. 1007-1136
[18]
European Community for Coal and Steel.
Standard lung function testing.
PHQuanjer. Report of working party on standardization of lung function test, 19 (1983), pp. 1-95
[19]
BR Celli, CG Cote, JM Marín, C Casanova, M Montes de Oca, RA Méndez, et al.
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.
N Engl J Med., 350 (2004), pp. 1005-1012
[20]
DA Mahler, JF Donohue, RA Barbee, MD Goldman, NJ Gross, ME Wisniewski, et al.
Efficacy of salmeterol xinafoate in the treatment of COPD.
Chest, 115 (1999), pp. 957-965
[21]
PM van Grunsven, CP van Schayck, JP Derenne, HAM Kerstjens, TEJ Renkema, DS Postma, et al.
Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Thorax, 54 (1999), pp. 7-14
[22]
JM Marín Trigo.
Manifestaciones clínicas: la disnea y su importancia en el paciente con EPOC.
Arch Bronconeumol., 37 (2001), pp. 8-13
[23]
JM Marín, SJ Carrizo, M Gascón, A Sánchez, B Gallego, BR Celli.
Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute walk test in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 163 (2001), pp. 1395-1399
[24]
MJ Belman, WC Botnick, JW Shin.
Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 153 (1996), pp. 967-975
[25]
M Miravitlles, C Mayordomo, M Artés, L Sánchez Agudo, F Nicolau, Segú JL on behalf of the EOLO Group.
Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.
Respir Med., 93 (1999), pp. 173-179
[26]
N Roche, T Legape, J Bourcereau, P Terrioux.
Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease.
Eur Respir J., 18 (2001), pp. 903-908
[27]
NR Anthonisen.
Steroids in COPD. The nearly eternal question.
Chest, 115 (1999), pp. 3-4
[28]
PW Jones.
Health status measurement in chronic obstructive pulmonary disease.
Thorax, 56 (2001), pp. 880-887
[29]
PW Jones, TK Bosh.
Quality of life changes in COPD patients treated with salmeterol.
Am J Respir Crit Care Med., 155 (1997), pp. 1238-1239
[30]
R Dahl, LAPM Greefhorst, D Nowak, V Nonikov, AM Byrne, MH Thomson, et al.
Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 164 (2001), pp. 778-784
[31]
M Miravitlles, JL álvarez-Sala, R Lamarca, M Ferrer, F Masa, H Verea, et al.
Treatment and quality of life in patients with chronic obstructive pulmonary disease.
Qual Life Res., 11 (2002), pp. 329-338
[32]
J Efthimiou, J Fleming, C Gomes, SG Spiro.
The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease.
Am Rev Respir Dis., 137 (1998), pp. 1075-1082
[33]
H Sahebjami, JT Doers, ML Render, TL Bond.
Anthropometric and pulmonary function test profile of outpatients with stable chronic obstructive pulmonary disease.
Am J Med., 94 (1993), pp. 469-474
[34]
H Sahebjami, E Sathianpitayakul.
Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med., 161 (2000), pp. 886-890
[35]
M Figueras.
Estimación del impacto de las prácticas asistenciales no recomendadas en el abordaje de la EPOC, Romargaf, (1999),
[36]
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD.
Chest, 121 (2002), pp. 1449-1455
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?